NCT01055067View on ClinicalTrials.gov

ARQ 197 for Participants With Relapsed or Refractory Germ Cell Tumors

PHASE2TerminatedINTERVENTIONAL

Enrollment

27

Participants

Timeline

Start Date

February 2, 2010

Primary Completion Date

November 30, 2011

Study Completion Date

November 30, 2011

Conditions

Non-CNS Germ Cell Tumors (Seminomas and Nonseminomas)

Interventions

DRUG

Tivantinib (ARQ 197)

Capsule, 120 mg, BID (360 mg), approximately 112 days

Trial Locations (10)

10065

New York

19104

Philadelphia

32806

Orlando

46202

Indianapolis

63110

St Louis

69373

Lyon

90033

Los Angeles

94800

Villejuif

LS9 7TF

Leeds

SM2 5PT

London

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Daiichi Sankyo

INDUSTRY